Novel strategies of protecting non-cancer cells during chemotherapy: are they ready for clinical testing?

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

6 citing papers in PubMed.

1. Cytotoxic and Antiproliferative Effects of Preussin, a Hydroxypyrrolidine Derivative from the Marine Sponge-Associated FungusMarine drugs · 2019
   Article
2. Protein kinase A type II-α regulatory subunit regulates the response of prostate cancer cells to taxane treatment.Cell cycle (Georgetown, Tex.) · 2014
   Article
3. Rapalogs in cancer prevention: anti-aging or anticancer?Cancer biology & therapy · 2012
   Review
4. Common drugs and treatments for cancer and age-related diseases: revitalizing answers to NCI's provocative questions.Oncotarget · 2012
   Article
5. Wt p53 impairs response to chemotherapy: make lemonade to spare normal cells.Oncotarget · 2012
   Article
6. Curtailing side effects in chemotherapy: a tale of PKCδ in cisplatin treatment.Oncotarget · 2012
   Review

Corrections and comments

• Comment on
  Exploring long-term protection of normal human fibroblasts and epithelial cells from chemotherapy in cell culture.2011

Authors and funding

1 author.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as